SEC Form SC 13G/A filed

2/8/21 10:19:29 AM ET

Medical/Dental Instruments

Health Care

Get the next $DXCM alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 7 DEXCOM INC COMMON STOCK Cusip #252131107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #252131107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,269,101 Item 6: 0 Item 7: 7,060,853 Item 8: 0 Item 9: 7,060,853 Item 11: 7.346% Item 12: HC Cusip #252131107 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 7,060,853 Item 8: 0 Item 9: 7,060,853 Item 11: 7.346% Item 12: IN Item 1(a). Name of Issuer: DEXCOM INC Item 1(b). Address of Issuer's Principal Executive Offices: 6340 Sequence Drive San Diego, CA 92121 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 252131107 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 7,060,853 (b) Percent of Class: 7.346% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 1,269,101 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 7,060,853 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of DEXCOM INC. No one other person's interest in the COMMON STOCK of DEXCOM INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 5, 2021 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 5, 2021, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of DEXCOM INC at December 31, 2020. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $DXCM alert in real time by email

Recent Analyst Ratings for

$DXCM

Date	Price Target	Rating	Analyst
1/12/2026	$71.00	Equal Weight → Underweight	Barclays
12/2/2025	$75.00	Equal-Weight → Overweight	Morgan Stanley
11/25/2025	$68.00	In-line	Evercore ISI
10/21/2025	$85.00	Buy	Stifel
9/8/2025		Outperform → Perform	Oppenheimer
8/21/2025	$100.00	Buy	Argus
6/16/2025	$102.00	Buy	Truist
5/30/2025	$104.00	Buy	Goldman

More analyst ratings

SEC Form SC 13G/A filed

2/8/21 10:19:29 AM ET

$DXCM

Medical/Dental Instruments

Health Care

Get the next $DXCM alert in real time by email

Recent Analyst Ratings for

$DXCM

Date	Price Target	Rating	Analyst
1/12/2026	$71.00	Equal Weight → Underweight	Barclays
12/2/2025	$75.00	Equal-Weight → Overweight	Morgan Stanley
11/25/2025	$68.00	In-line	Evercore ISI
10/21/2025	$85.00	Buy	Stifel
9/8/2025		Outperform → Perform	Oppenheimer
8/21/2025	$100.00	Buy	Argus
6/16/2025	$102.00	Buy	Truist
5/30/2025	$104.00	Buy	Goldman

More analyst ratings

SEC Form SC 13G/A filed

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$DXCM

SEC Form SC 13G/A filed

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$DXCM

$DXCM
Press Releases

Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026

Dexcom Appoints Rick Osterloh to Board of Directors

Dexcom Announces Upcoming Conference Presentation

$DXCM
Analyst Ratings

Dexcom downgraded by Barclays with a new price target

Dexcom upgraded by Morgan Stanley with a new price target

Evercore ISI initiated coverage on Dexcom with a new price target

$DXCM
Insider Trading

SEC Form 4 filed by Brown Michael Jon

EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)

Executive Chair Sayer Kevin R was granted 32,749 shares and covered exercise/tax liability with 32,498 shares, increasing direct ownership by 0.06% to 409,241 units (SEC Form 4)

$DXCM
Insider Purchases

President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

$DXCM
SEC Filings

DexCom Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-K filed by DexCom Inc.

$DXCM
Leadership Updates

Dexcom Appoints Rick Osterloh to Board of Directors

Dexcom Appoints Euan Ashley to Board of Directors

Synchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D

$DXCM
Financials

Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

$DXCM
Large Ownership Changes